Non-invasive biomarkers for monitoring portal hypertension in metabolic dysfunction-associated steatotic liver disease (MASLD).

INTRODUCTION

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the leading cause of chronic liver disease worldwide and a major cause of morbidity and mortality. Portal hypertension (pHTN), previously thought to occur only with cirrhosis, is now recognized in MASLD even before advanced fibrosis, due to endothelial dysfunction and increased portal pressure. This underscores the need for early, noninvasive detection and treatment.

AREAS COVERED: This review examines the pathophysiological mechanisms leading to pHTN in MASLD, highlighting the role of vascular remodeling and endothelial dysfunction in portal pressure elevation. Although hepatic venous pressure gradient remains the gold standard for diagnosis, its invasive nature requires alternative strategies. This article discusses emerging noninvasive techniques, including imaging modalities and circulating biomarkers reflecting intrahepatic resistance, liver injury, and inflammation, that may improve early detection and risk stratification of pHTN in MASLD. A comprehensive literature search was performed in PubMed and Embase for studies published between January 2000 and June 2025.

EXPERT OPINION: Given the increasing burden of MASLD, noninvasive assessment of pHTN is essential. The combination of imaging and biomarkers could improve diagnosis and guide treatment. Future research should validate these tools and develop targeted therapies to prevent pHTN progression and improve outcomes.